Beautiful Mornin' for Oklahoma's Selexys as it bags $665m Novartis option and venture round
This article was originally published in Scrip
A Series A financing concurrent with a Big Pharma option to buy your lead drug candidate? The scenario is not as elusive as it may seem, since the US venture Selexys Pharmaceuticals - like other private companies since MPM Capital began managing investment funds for Novartis Pharmaceuticals in 2007 - has achieved both financial milestones in one fell swoop.
You may also be interested in...
Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio
Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.
Novartis Buys Selexys As Competitors Stumble In Sickle Cell
Novartis has exercised its option to acquire Selexys in a deal worth up to $665m, following data from the Phase II SUSTAIN trial of SelG1 in sickle cell disease. The move follows several recent failures in the space.
Finance Watch: Ferring Shutters San Diego R&D Site As Even Money-Making Firms Cut Costs
Restructuring Edition: After reporting record revenue, but lower profits due to rising costs, Ferring has decided to consolidate R&D in Europe. Also, Codiak has filed for Chapter 11 bankruptcy and will sell off its assets, while Exicure, Applied Molecular Transport, Gamida Cell and others revealed new job cuts.